What do systematic reviews say?

Tacrolimus vs cyclosporin

Tacrolimus showed no clear difference in mortality Mortality at latest compared with cyclosporin (low certainty).

• Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients 2013 · Cochrane Headline outcomes only
  RR 1.06 [0.75, 1.49]
  3 studies · 413 participants
  Low

Tacrolimus vs cyclosporin

Tacrolimus showed no clear difference in acute rejection The number of patients who experienced at least one… compared with cyclosporin (low certainty).

• Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients 2013 · Cochrane Headline outcomes only
  RR 0.89 [0.77, 1.05]
  2 studies · 323 participants
  Low

Tacrolimus vs cyclosporin

Tacrolimus probably leads to lower bronchiolitis obliterans syndrome The number of patients diagnosed… compared with cyclosporin (moderate certainty).

• Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients 2013 · Cochrane Headline outcomes only
  RR 0.46 [0.29, 0.74]
  3 studies · 413 participants
  Moderate

Tacrolimus vs cyclosporin

• Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients 2013 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 74 participants
  Low

Tacrolimus vs cyclosporin

Tacrolimus may leads to lower treatment withdrawal the number of patients stopping the assigned… compared with cyclosporin (low certainty).

• Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients 2013 · Cochrane Headline outcomes only
  RR 0.27 [0.16, 0.46]
  3 studies · 413 participants
  Low

Tacrolimus vs cyclosporin

Tacrolimus may leads to lower arterial hypertension compared with cyclosporin (low certainty).

• Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients 2013 · Cochrane Headline outcomes only
  RR 0.67 [0.5, 0.89]
  2 studies · 164 participants
  Low

Tacrolimus vs cyclosporin

Tacrolimus may leads to higher diabetes mellitus compared with cyclosporin (low certainty).

• Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients 2013 · Cochrane Headline outcomes only
  RR 4.24 [1.58, 11.4]
  2 studies · 164 participants
  Low

Tacrolimus vs cyclosporin

Tacrolimus showed no clear difference in treatment response at 6 months: complete remission compared with cyclosporin (low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 1.14 [0.64, 2.03]
  1 study · 41 participants
  Low

Tacrolimus vs cyclosporin

Tacrolimus showed no clear difference in treatment response at 6 months: complete and partial remission compared with cyclosporin (low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 0.57 [0.16, 2.08]
  1 study · 41 participants
  Low
• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 1.05 [0.87, 1.25]
  2 studies · 58 participants
  Low

Tacrolimus vs cyclosporin

Tacrolimus showed no clear difference in treatment response at 12 months: complete remission compared with cyclosporin (low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 0.8 [0.45, 1.42]
  2 studies · 58 participants
  Low

Tacrolimus vs cyclosporin

Tacrolimus showed no clear difference in adverse events: persistent nephrotoxicity compared with cyclosporin (low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 0.48 [0.05, 4.85]
  1 study · 41 participants
  Low

Tacrolimus vs cyclosporin

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 58 participants
  Low

Tacrolimus vs mycophenolate mofetil to maintain remission

Tacrolimus may leads to higher number with complete or partial response at one year compared with mycophenolate mofetil to maintain remission (low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 2.01 [1.32, 3.07]
  1 study · 60 participants
  Low

Tacrolimus vs mycophenolate mofetil to maintain remission

Tacrolimus may leads to higher number with complete response at one year compared with mycophenolate mofetil to maintain remission (low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 1.79 [1.11, 2.9]
  1 study · 60 participants
  Low

Tacrolimus vs mycophenolate mofetil to maintain remission

Tacrolimus showed no clear difference in number with partial response at one year compared with mycophenolate mofetil to maintain remission (low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 4.68 [0.58, 37.68]
  1 study · 60 participants
  Low

Tacrolimus vs mycophenolate mofetil to maintain remission

Tacrolimus may leads to lower number with treatment failure by one year compared with mycophenolate mofetil to maintain remission (low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 0.18 [0.06, 0.54]
  1 study · 60 participants
  Low

Tacrolimus vs mycophenolate mofetil to maintain remission

Tacrolimus may leads to lower number with frequent relapses by one year compared with mycophenolate mofetil to maintain remission (low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 0.28 [0.09, 0.92]
  1 study · 60 participants
  Low

Tacrolimus vs mycophenolate mofetil to maintain remission

Tacrolimus showed no clear difference in number with steroid resistance by one year compared with mycophenolate mofetil to maintain remission (low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 0.07 [0, 1.23]
  1 study · 60 participants
  Low

Tacrolimus vs mycophenolate mofetil to maintain remission

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 60 participants
  Low

Mycophenolate mofetil (MMF) + tacrolimus (TAC) vs IV cyclophosphamide

Mycophenolate mofetil (MMF) + tacrolimus (TAC) showed no clear difference in partial renal remission compared with IV cyclophosphamide (CPA) (low certainty).

• Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
  RR 1 [0.78, 1.28]
  2 studies · 402 participants
  Low